NCT02983006 - Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

December 23, 2019

Study Completion Date

January 1, 2021

Conditions

Melanoma

Interventions

BIOLOGICAL

DS-8273a

"* Starting Dose: 4 mg/ kg IVQ 3 weeks (Cohort 1)~* Dose Escalation: 8 mg/kg IV Q 3 weeks (Cohort 2), 16 mg/kg IV Q 3 weeks (Cohort 3), 24 mg/kg IV Q 3 weeks (Cohort 4), 2 mg/kg IV Q 3 weeks (Cohort -1), 4 mg/kg IV Q 3 weeks (Cohort -2)"

BIOLOGICAL

Nivolumab

5 mg/kg IV Q 3 weeks

Trial Locations (1)

10016

Laura and Isaac Perlmutter Cancer Center, New York